SSKN — STRATA Skin Sciences Income Statement
0.000.00%
- $10.97m
- $18.90m
- $33.56m
- 43
- 53
- 34
- 39
Annual income statement for STRATA Skin Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 23.1 | 30 | 36.2 | 33.4 | 33.6 |
Cost of Revenue | |||||
Gross Profit | 14.1 | 19.9 | 21.8 | 18.5 | 19.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 27.2 | 32.4 | 40.8 | 42.9 | 42.8 |
Operating Profit | -4.08 | -2.37 | -4.65 | -9.51 | -9.26 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.14 | -2.67 | -5.49 | -10.9 | -10.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.41 | -2.71 | -5.55 | -10.8 | -10.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.41 | -2.71 | -5.55 | -10.8 | -10.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.41 | -2.71 | -5.55 | -10.8 | -10.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.31 | -1.21 | -1.59 | -2.49 | -1.95 |